The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Early discontinuation of tamoxifen: A Lesson for oncologists
Open accessAbstract
BACKGROUND.: Five years of treatment provides the optimum duration of tamoxifen therapy for the prevention of breast cancer recurrence and mortality. Durations of adjuvant tamoxifen therapy less than 5 years are associated with poorer outcomes for breast cancer patients. The purpose of the study was to assess rates of tamoxifen nonpersistence (early discontinuation) in women aged 35 years or older using prescription refill data from a national prescribing database. METHODS.: A cohort of 2816 women commencing tamoxifen as initial hormonal therapy was identified between January 2001 and January 2004. The cumulative tamoxifen persistence rate was calculated for these women and the relation between nonpersistence and clinical and demographic variables assessed. RESULTS.: Within 1 year of commencing treatment the cumulative tamoxifen nonpersistence rate was 22.1%. This is twice the rate of treatment discontinuation observed in other studies by this time. By the end of follow‐up at 3.5 years, the cumulative nonpersistence rate had increased to 35.2%. Determinants of nonpersistence identified included age and a history of antidepressant use. CONCLUSIONS.: The rate of nonpersistence with tamoxifen therapy is higher than previously reported. This study demonstrates that persistence with tamoxifen cannot be assumed and raises concerns about persistence with other oral hormonal therapies for breast cancer and oral antineoplastics in general. Oncologists need to identify those at risk of nonpersistence and develop strategies to combat this barrier to treatment success. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,079
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Influence of psychological response on survival in breast cancer: a population-based cohort study
Watson, M., Haviland, J., Greer, S., Davidson, J., & Bliss, J. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11392-2 · Cited by 705
Cited by
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
The impact of comorbidity on cancer survival: a review
Sogaard, M., W. Thomsen, R., Bossen, Henrik Toft Sørensen, H., & Nørgaard, M. (2013) · Clinical Epidemiology · doi:10.2147/clep.s47150 · Cited by 603
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5422 · Cited by 529
Self-citationRaebel, M. A., Schmittdiel, J., Karter, A. J., Konieczny, J. L., & Steiner, J. F. (2013) · Medical Care · doi:10.1097/mlr.0b013e31829b1d2a · Cited by 485
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., & Asnis-Alibozek, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5451 · Cited by 482
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Neugut, A. I., Subar, M., Wilde, E. T., Stratton, S., Brouse, C. H., Hillyer, G. C., Grann, V. R., & Hershman, D. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3179 · Cited by 354
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
“Non-persistence with tamoxifen therapy at 1 year differed from the figure reported in the study by Barron et al (2007) but at three and a half years was at a similar Table 2 Clinical and pathological characteristics of cancer at initial diagnosis Patients with tamoxifen (”
BackgroundMethodResultInfluentialOwusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M., & McCowan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.116 · Cited by 298
“…pharmacy records have reported poor persistence with tamoxifen, with between one-third to half of the women stopping their medication early and up to 22% having stopped by 1 year (Barron et al, 2007; Ma et al, 2008; McCowan et al, 2008; Owusu et al, 2008; Narod, 2010; van Herk-Sukel et al, 2010).”
BackgroundWheeler, S. B., Reeder-Hayes, K. E., & Carey, L. A. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0243 · Cited by 275
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U.-S., Holzhauer, W., Ziller, M., Wagner, U., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263
Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., & Van Hecke, A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.014 · Cited by 202
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
McCowan, C., Wang, S., Thompson, A. M., Makubate, B., & Petrie, D. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.464 · Cited by 137
Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr330 · Cited by 133
Atema, V., van Leeuwen, M., Kieffer, J. M., Oldenburg, H. S. A., van Beurden, M., Gerritsma, M. A., Kuenen, M. A., Plaisier, P. W., Lopes Cardozo, A. M. F., van Riet, Y. E. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00655 · Cited by 105
Huiart, L., Bouhnik, A.-D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M. K., Viens, P., & Giorgi, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.004 · Cited by 97
Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7367 · Cited by 91
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Self-citationZiller, V., Kyvernitakis, I., Knöll, D., Storch, A., Hars, O., & Hadji, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-407 · Cited by 82
Font, R., Espinas, J. A., Gil-Gil, M., Barnadas, A., Ojeda, B., Tusquets, I., Segui, M. A., Margelí, M., Arcusa, A., Prat, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.389 · Cited by 79
Ayres, L. R., Baldoni, A. D. O., Borges, A. P. D. S., & Pereira, L. R. L. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9833-5 · Cited by 65
Winn, A. N., & Dusetzina, S. B. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4012 · Cited by 57
Seruga, B., & Tannock, I. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5594 · Cited by 53
Yu, K.-D., Zhou, Y., Liu, G.-Y., Li, B., He, P.-Q., Zhang, H.-W., Lou, L.-H., Wang, X.-J., Wang, S., Tang, J.-H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2059-8 · Cited by 50
The pharmacological and hormonal therapy of hot flushes in breast cancer survivors
Wiśniewska, I., Jochymek, B., Lenart-Lipińska, M., & Chabowski, M. (2016) · Breast Cancer · doi:10.1007/s12282-015-0655-2 · Cited by 36
Boukhechba, M., Baee, S., Nobles, A. L., Gong, J., Wells, K., & Barnes, L. E. (2018) · 2018 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI) · doi:10.1109/bhi.2018.8333422 · Cited by 10
Metadata
- Authors
- Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-01-22
- Volume
- 109
- Issue
- 5
- Pages
- 832-839
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1519097020
- Cited by
- 279
- References
- 41
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.